Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | GLS | O94925 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2393006 | 0.82 | PIN1 (0.47) | CYP2C19CYP2C9HTTKMT2AGLS | |
| SCHEMBL29524567 | 0.82 | PIN1 (0.47) | CYP2C19CYP2C9HTTKMT2AGLS | |
| SCHEMBL31383801 | 0.81 | CYP2C19 (0.49) | CYP2C19CYP2C9HTTKMT2AALDH1A1 | |
| SCHEMBL1345452 | 0.81 | CYP2C19 (0.49) | CYP2C19CYP2C9HTTKMT2AALDH1A1 | |
| SCHEMBL9126501 | 0.81 | CYP2C19 (0.46) | CYP2C19CYP2C9HTTKMT2AALDH1A1 | |
| SCHEMBL30078420 | 0.81 | CYP2C19 (0.46) | CYP2C19CYP2C9HTTKMT2AALDH1A1 | |
| SCHEMBL18698687 | 0.81 | KMT2A (0.49) | CYP2C19CYP2C9HTTKMT2AALDH1A1 | |
| SCHEMBL30574489 | 0.80 | CYP2C19 (0.44) | CYP2C19CYP2C9HTTKMT2AALDH1A1 | |
| SCHEMBL21296572 | 0.80 | CYP2C19 (0.44) | CYP2C19CYP2C9HTTKMT2AALDH1A1 | |
| SCHEMBL5050643 | 0.80 | HTT (0.47) | CYP2C19CYP2C9HTTKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12404295-B2 | (Hetero)aryl-methyl-thio-beta-D-galactopyranoside derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2025-09-02 | — | — | US | disclosed |
| EP-4010076-B1 | (HETERO)ARYL-METHYL-THIO-BETA-D-GALACTOPYRANOSIDE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2024-01-17 | — | — | EP | disclosed |
| US-20220315619-A1 | (HETERO)ARYL-METHYL-THIO-BETA-D-GALACTOPYRANOSIDE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2022-10-06 | — | — | US | disclosed |
| EP-4010076-A1 | (HETERO)ARYL-METHYL-THIO-BETA-D-GALACTOPYRANOSIDE DERIVATIVES | Idorsia Pharmaceuticals Ltd (CH) | 2022-06-15 | — | — | EP | disclosed |
| CN-114206893-A | (hetero) aryl-methyl-thio-beta-D-galactopyranoside derivatives | 爱杜西亚药品有限公司 | 2022-03-18 | — | — | CN | disclosed |
| WO-2021028336-A1 | (HETERO)ARYL-METHYL-THIO-BETA-D-GALACTOPYRANOSIDE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-02-18 | — | — | WO | disclosed |
| EP-2511273-B1 | Inhibitors of viral replication, their process of preparation and their therapeutical uses | HIVIH (FR) | 2019-05-15 | — | — | EP | disclosed |
| EP-2511273-B1 | Inhibitors of viral replication, their process of preparation and their therapeutical uses | HIVIH (FR) | 2019-05-15 | — | — | EP | disclosed |
| EP-2697213-B1 | INHIBITORS OF VIRAL REPLICATION, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES | HIVIH (FR) | 2018-12-12 | — | — | EP | disclosed |
| US-9604900-B2 | Inhibitors of viral replication, their process of preparation and their therapeutical uses | LABORATOIRE BIODIM (FR) | 2017-03-28 | — | — | US | disclosed |
| EP-2091922-B1 | 2-[1-PHENYL-5-HYDROXY-4ALPHA-METHYL-HEXAHYDROCYCLOPENTA[F]INDAZOL-5-YL]ETHYL PHENYL DERIVATIVES AS GLUCOCORTICOID RECEPTOR LIGANDS | MERCK SHARP & DOHME (US) | 2011-12-21 | — | — | EP | disclosed |
| WO-2011053574-A1 | 2- [1-PHENYL-5-HYDROXY-4a-SUBSTITUTED-HEXAHYDROCYCLOPENTA [F] INDAZOL-5-YL] ETHYL PHENYL DERIVATIVES AS GLUCOCORTICOID RECEPTOR LIGANDS | MERCK SHARP & DOHME CORP. (US) | 2011-05-05 | — | — | WO | disclosed |
| US-20100311709-A1 | 2-[1-PHENYL-5-HYDROXY OR METHOXY-4ALPHA-METHYL-HEXAHYDROCYCLOPENTA [f]INDAZOLE-5-YL]ETHYL PHENYL DERIVATIVES AS GLUCOCORTICOID RECEPTOR LIGANDS | MERCK SHARP & DOHME CORP. | 2010-12-09 | — | — | US | disclosed |
| US-20100311709-A1 | 2-[1-PHENYL-5-HYDROXY OR METHOXY-4ALPHA-METHYL-HEXAHYDROCYCLOPENTA [f]INDAZOLE-5-YL]ETHYL PHENYL DERIVATIVES AS GLUCOCORTICOID RECEPTOR LIGANDS | MERCK SHARP & DOHME CORP. | 2010-12-09 | — | — | US | disclosed |
| US-20100311709-A1 | 2-[1-PHENYL-5-HYDROXY OR METHOXY-4ALPHA-METHYL-HEXAHYDROCYCLOPENTA [f]INDAZOLE-5-YL]ETHYL PHENYL DERIVATIVES AS GLUCOCORTICOID RECEPTOR LIGANDS | MERCK SHARP & DOHME CORP. | 2010-12-09 | — | — | US | disclosed |
| EP-2097385-A1 | 2-[1-PHENYL-5-HYDROXY OR METHOXY-4ALPHA-METHYL-HEXAHYDROCLOPENTA[F]INDAZOL-5-YL]ETHYL PHENYL DERIVATIVES AS GLUCOCORTICOID RECEPTOR LIGANDS | Merck & Co., Inc. (US) | 2009-09-09 | — | — | EP | disclosed |
| CN-101528707-A | 2- [ 1-phenyl-5-hydroxy or methoxy-4 alpha-methyl-hexahydrocyclopenta [ f ] indazol-5-yl ] ethylphenyl derivatives useful as glucocorticoid receptor ligands | MERCK & CO INC (US) | 2009-09-09 | — | — | CN | disclosed |
| WO-2008060391-A2 | 2- [L-PHENYL-5-HYDR0XY-4ALPHA-METHYL-HEXAHYDR0CYCL0PENTA[F] INDAZ0L-5-YL] ETHYL PHENYL DERIVATIVES AS GLUCOCORTICOID RECEPTOR LIGANDS | MERCK & CO., INC. (US) | 2008-05-22 | — | — | WO | disclosed |
| WO-2008051532-A1 | 2-[1-PHENYL-5-HYDROXY OR METHOXY-4ALPHA-METHYL-HEXAHYDROCLOPENTA[F]INDAZOL-5-YL]ETHYL PHENYL DERIVATIVES AS GLUCOCORTICOID RECEPTOR LIGANDS | MERCK & CO., INC. (US) | 2008-05-02 | — | — | WO | disclosed |
| WO-2008051532-A1 | 2-[1-PHENYL-5-HYDROXY OR METHOXY-4ALPHA-METHYL-HEXAHYDROCLOPENTA[F]INDAZOL-5-YL]ETHYL PHENYL DERIVATIVES AS GLUCOCORTICOID RECEPTOR LIGANDS | MERCK & CO., INC. (US) | 2008-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315619-A1 | (HETERO)ARYL-METHYL-THIO-BETA-D-GALACTOPYRANOSIDE DERIVATIVES | LGALS1, LGALS3, LGALS2 | CYP2C19 1973/4885CYP2C9 1915/4885HTT 1755/4885 |
| US-12404295-B2 | (Hetero)aryl-methyl-thio-beta-D-galactopyranoside derivatives | LGALS1, LGALS3, LGALS2 | CYP2C19 1973/4885CYP2C9 1915/4885HTT 1755/4885 |
| US-20100311709-A1 | 2-[1-PHENYL-5-HYDROXY OR METHOXY-4ALPHA-METHYL-HEXAHYDROCYCLOPENTA [f]INDAZOLE-5-YL]ETHYL PHENYL DERIVATIVES AS GLUCOCORTICOID RECEPTOR LIGANDS | NR3C1, NR3C2, NR5A1 | CYP2C19 720/4885CYP2C9 1092/4885HTT 3948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.